Gupta V, Kim S, Hu Z-H, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1(−) MPN with de novo AML and with AML following MDS. Blood Adv. 2020;4(19):4748-4757.

Similar Items

• Comparison of outcomes of HCT in blast phase of BCR-ABL1(−) MPN with de novo AML and with AML following MDS
  od: Gupta, Vikas, i dr.
  Izdano: (2020)
• Gupta V, Kennedy JA, Capo-Chichi J-M, et al. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase. Blood Adv. 2020;4(21):5562-5573.
  Izdano: (2021)
• Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase
  od: Gupta, Vikas, i dr.
  Izdano: (2020)
• Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
  od: Mestrum, Stefan G. C., i dr.
  Izdano: (2020)
• Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML
  od: Tefferi, A, i dr.
  Izdano: (2009)